Glutamatergic deficit and schizophrenia-like negative symptoms: new evidence from ketamine-induced m...
Glutamatergic deficit and schizophrenia-like negative symptoms: new evidence from ketamine-induced mismatch negativity alterations in healthy male humans
About this item
Full title
Author / Creator
Publisher
Canada: Joule Inc
Journal title
Language
English
Formats
Publication information
Publisher
Canada: Joule Inc
Subjects
More information
Scope and Contents
Contents
Targeting the
-methyl-D-aspartate receptor (NMDAR) is a major translational approach for treating negative symptoms of schizophrenia. Ketamine comprehensively produces schizophrenia-like symptoms, such as positive, cognitive and negative symptoms in healthy volunteers. The amplitude of the mismatch negativity (MMN) is known to be significantly r...
Alternative Titles
Full title
Glutamatergic deficit and schizophrenia-like negative symptoms: new evidence from ketamine-induced mismatch negativity alterations in healthy male humans
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5487274
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5487274
Other Identifiers
ISSN
1180-4882
E-ISSN
1488-2434
DOI
10.1503/jpn.160187
